Zobrazeno 1 - 6
of 6
pro vyhledávání: '"E V Makhnova"'
Autor:
E V Makhnova
Publikováno v:
Современная онкология, Vol 5, Iss 3, Pp 127-131 (2003)
Закономерно, что неудовлетворительные в целом результаты химиотерапии рецидивов и платинорезистентных форм распространенного рака яи
Externí odkaz:
https://doaj.org/article/ef61c7fd03de4a139f7e0530a7cd783e
Publikováno v:
Voprosy onkologii. 52(5)
Therapy of anemia raises hemoglobin (Hb) level which in turn improves quality of life. Venofer was tested in 20 anemic (grade 1) patients with various malignancies. The drug was administered in 3 courses, i/v, 200 mg at a 4-5 week interval during che
Publikováno v:
Voprosy onkologii. 50(6)
A clinical appraisal of efficacy and tolerability of taxol (T) and a generic drug--paclitaxel--LANCE (P)--was carried out in two groups of patients with recurrences (9) or platinum-refractory ovarian carcinoma (17). In group I, patients aged 19-71 (m
Publikováno v:
Voprosy onkologii. 49(4)
Ondanserton (zofran), 16-32 mg/24 hr, lingual tablets, 2 days, was administered in 40 patients with advanced tumors who received combination chemotherapy (ABVD) (9 patients with Hodgkin's disease), CHOP (16--non-Hodgkin's lymphoma), gemzar + cisplati
Autor:
E V, Makhnova, M L, Gershanovich
Publikováno v:
Voprosy onkologii. 49(2)
The effectiveness and tolerability of xeloda (capecitabine), a tumor-reactivated oral fluoropyrimidine, alone were investigated in 19 patients, aged 39-79, with relapsing and cisplatin-resistant ovarian tumors. Unfavorable prognosis of chemotherapy w
Autor:
E V, Makhnova
Publikováno v:
Voprosy onkologii. 49(1)
The paper is concerned with the data on treatment of 33 patients with advanced ovarian cancer, aged 34-72 (average age of 52.5). Having received numerous regimens of combination chemotherapy, mainly, with cisplatin-containing drugs, sixty-one percent